Global Cell-Based Assays Market to Exceed $1.5 Billion by 2017, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Cell-Based Assays markets. The global market for Cell-Based Assays is forecast to cross US$1.5 billion by 2017. Principal factors driving the market include growing demand by drug development companies for the expansion of their drug portfolios; increased usage as a preferred tool for screening potential drug compounds; and increase in the number of drug targets being screened through genomics and proteomics applications. The market for Cell-Based Assays is likely to expand further due to the presence of a million proteins with unknown functions, and the need for improved drug development processes.

Cell-Based Assays: A Global Strategic Business Report

Follow us on LinkedIn – The demand for cell-based assays is largely being fuelled by the drug discovery industry. A notable trend is the use of cell-based assays in every phase of the drug discovery process, specifically High Throughput Screening (HTS), which witnessed substantial growth during the past few years. Cell-based assays currently represent an important segment of the drug discovery industry, with nearly 50% of all the assays focused on primary high throughput screening, and about 55% concentrated on selectivity screens. Characterized by versatility, cell-based assays represent a powerful research tool that facilitates in providing valuable information to the research and development community. Cell-based assays facilitate in studying the biological implication of various compounds, such as drugs, on cells as well as cellular systems. Cell-based assays could be further utilized in monitoring the biological implications of changes in the external environment, such as activation of cell receptor, stress, external stimuli, and alteration of gene activity and expression of proteins. Cell-based assays are emerging as the preferred tool for screening potential drug compounds as they facilitate in gaining access to a number of therapeutic targets. Further, cell-based assays also facilitate the study of toxic effects and metabolism in the early stages of drug discovery, thereby reducing the overall costs. The market is driven by advanced technological innovations as well as high throughput screening (HTS) systems.

Over the years, automation, the use of microfluidics systems, an increasing use in toxicity testing, and the development of label-free cell-based assays are some of the notable trends in the market for cell-based assays. Important growth drivers include new and enhanced screening technologies, automation, and non-invasive monitoring of cell-based assays. Cell-based assays are expected to continue to be a commercial success owing to its growing demand by drug development companies for the expansion of their drug portfolios. Although competitive technologies that provide similar analyses are expected to impinge on the market growth, the value provided by cell-based assays would possibly not be replaceable by a single methodology. Moreover, high-throughput processing of samples is likely to drive down per sample costs, facilitating the market to achieve economies of scale. However, certain market challenges do exist, which include costs, reagent stability, statistics, and robustness.

Regionally, the US and Europe are the major markets worldwide, as stated by the new market research report on Cell-based Assays. In the US, functional cell assays continued its dominance in the market as the largest segment in terms of revenues, driven by factors such as relative newness in the market and increasing adoption. Going forwards, the segment is expected to witness its share increasing with the growing demand for the analysis of functional events. Meanwhile, the cell death-based assays too are projected to witness substantial growth, driven by associated technical aspects of these assays that demand relatively higher cost for each experiment when compared to cell growth-based assays. Growth-wise, developed markets, including Europe and the US, are forecast to exhibit the fastest growth, with Europe expected to grow at a compounded annual growth rate of 11.82% during the analysis period.

Use of in-vitro test methods in toxicity testing is anticipated to take over in-vivo as well as animal model testing methods in the coming years. Cell-based assays are expected to emerge as a vital technology in serving this purpose, given their role either as a part of a tiered testing scheme or as test batteries in predicting human toxicity endpoints. However, the use of cell-based assays in toxicity testing is a time consuming process with a number of regulatory hurdles. Thus far, only a few stand-alone cell-based assays have been approved for completely replacing assays based on animal models, while some others have been validated for use as a part of a tiered testing scheme or as screening assays. Functional Cell Assays facilitate in gaining a better understanding of the mechanisms associated with the expression of toxic effects in humans and animals by analyzing specific functional responses. High Throughput/High Content (HTS/HCS) cell-based assays enable the evaluation of several toxicity endpoints, which is expected to enable the identification of various aspects associated with the onset of cell stress. This, in turn, aids in predicting specific cytotoxic effects.

Major players profiled in the report include BD Biosciences, Beckman Coulter Inc., BioVision Inc., Caliper Life Sciences Inc., Cisbio Bioassays, DiscoveRx Corp., GE Healthcare Life Sciences, Life Technologies, EMD Millipore, PerkinElmer Inc., Promega Corporation, ProQinase GmbH, Thermo Fisher Scientific Inc., Sigma-Aldrich, Xenometrix AG, among others.

The research report titled “Cell-Based Assays: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the market, current market trends, key growth drivers, recent product introductions, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for cell-based assays for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World. The report also analyses the US market for Cell-based Assays by the following product segments – Assay Kits (Functional Assays, Cell Death-Associated Assays, Cell Growth-Associated Assays), and Laboratory Automation. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Cell_Based_Assays_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website